title: Effects of bopindolol on platelet function in hypertension at rest and during exercise.
abstract: The effects of bopindolol, a new nonselective beta-blocking agent, on platelet function have been studied in 10 male hypertensive patients given the drug (1 mg/day) in turn for eight weeks. Bopindolol significantly (p less than 0.01) decreased the bicycle exercise- (1.5 W/kg body weight for 6 minutes) induced increase in platelet aggregation. During bopindolol-treatment both the slope and the height of the platelet aggregation response curve were moderately decreased at rest before exercise and significantly (p less than 0.05) decreased at rest after exercise. During exercise the slope amounted to 75.4 +/- 44 degrees before and to 70.8 +/- 5.3 degrees after therapy (p less than 0.01), the height to 64.0 +/- 11.9% before and to 58.1 +/- 14.7% (p less than 0.05) after therapy. Furthermore, bopindolol significantly increased the exercise-induced decrease in platelet sensitivity to PGI2 (p less than 0.05; IC-50-value: 2.10 +/- 0.47 vs 1.88 +/- 0.31 ng/ml) and PGD2 (p less than 0.05; IC-50-value: (19.88 +/- 2.10 vs 18.57 +/- 1.63 ng/ml). Bopindolol also significantly (p less than 0.05) decreased the exercise-induced elevation in serum-TXB2 (244.9 +/- 35.2 vs 237.3 +/- 27.2 ng/ml) and plasma-TXB2 (15.7 +/- 6.3 vs 13.1 +/- 3.7 pg/ml). The platelet count, the plasma levels of 6-oxo-PGF1 alpha, beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4) were not affected by bopindolol. It is concluded that bopindolol favourably affects platelet function, in that it lowers exercise-induced platelet aggregation and TXB2-formation in therapeutical doses and increases platelet sensitivity to antiaggregatory prostaglandins.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Atherosclerosis Research Group (ASF) Vienna, University of Vienna, Austria.
authors: I
authors: I
authors: Virgolini
authors: P
authors: P
authors: Fitscha
authors: F
authors: F
authors: Rauscha
authors: H
authors: H
authors: Sinzinger
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000328:Adult; D001481:Basal Metabolism; D001792:Blood Platelets / Q000187:drug effects*; D011464:Epoprostenol / Q000494:pharmacology; D015444:Exercise; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D010974:Platelet Aggregation; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000378:metabolism; D015230:Prostaglandin D2 / Q000494:pharmacology; D013929:Thromboxane B2 / Q000097:blood / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
chemical_list: D001620:beta-Thromboglobulin; D010978:Platelet Factor 4; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D010869:Pindolol; D011464:Epoprostenol; C036007:bopindolol; D015230:Prostaglandin D2